Notable Call Buying Activity in Teva Pharma (TEVA) Continues -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
'Bullish Options Flow' in Teva Pharma (TEVA) Continues -Susquehanna
December 1, 2017 2:42 PM ESTSusquehanna options strategist Alison Edwards notes continued bullish options flow in Teva Pharma (NYSE: TEVA), as investors sold 5k Dec 14 Calls at $1.83 closing to buy 7k Dec 15 Calls $for 1.10, opening. Trading makes investor long ~30k Dec 156 calls. Also today, investors bought 13k Jan 17.5... More
Teva Pharma (TEVA) PT Raised to $16 at Mizuho Securities on Announced Major Cost Cuts
November 29, 2017 6:45 AM ESTMizuho Securities raised its price target on Teva Pharma (NYSE: TEVA) to $16.00 (from $12.00) while maintaining a Neutral rating, following a model update fueled by conversations with management.
Analyst Irina Koffler notes a positive outlook on the shares, following conversations with management... More
Teva Pharma (TEVA) Announces New Organization Structure, Leadership Changes
November 27, 2017 9:03 AM ESTTeva Pharmaceutical Industries Ltd. (NYSE & TASE: TEVA) announced today a new organization and leadership structure aimed to achieve better commercial focus and drive value creation. The new structure will enable strategic alignment across the portfolio, across regions and between functions, leveraging scale, enhancing agility, extracting efficiencies and providing increased proximity to the markets. This new structure will be implemented effective immediately.
... More
Teva Pharma (TEVA) Says It Isn't Planning to Divest Oncology/Pain Assets, Reassessed Situation - Bloomberg
November 27, 2017 8:27 AM ESTTeva Pharma (NYSE: TEVA) Says It Isn't Planning to Divest Oncology/Pain Assets, Reassessed Situation - Bloomberg
... More